FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00656 FOSUN INTL

Not Yet Opened 02-03 16:08:20

4.120

+0.000

0.00%

High4.140	Low4.000	Vol12.90M
Open4.120	D1 Closing4.120	Amplitude3.40%
Mkt Cap33.65B	Tradable Cap33.65B	Total Shares8.17B
T/O52.56M	T/O Rate0.16%	Tradable Shares8.17B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00656","market":"HK","secType":"STK","nameCN":"FOSUN INTL","latestPrice":4.12,"timestamp":1770106100003,"preClose":4.12,"halted":0,"volume":12904232,"delay":0,"changeRate":0,"floatShares":8167000000,"shares":8167000000,"eps":-0.6022566023891185,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-03 16:08:20","open":4.12,"high":4.14,"low":4,"amount":52556717,"amplitude":0.033981,"askPrice":4.12,"askSize":124500,"bidPrice":4.11,"bidSize":119000,"shortable":3,"etf":0,"ttmEps":-0.610951053571568,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":0,"adr":0,"listingDate":1184515200000,"exchange":"SEHK","adjPreClose":4.12,"dividendRate":0.004879,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":0.952648,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00656","defaultTab":"news","newsList":[{"id":"2608082494","title":"Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2608082494","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608082494?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:09","pubTimestamp":1770113346,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3z8m75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","600036","LU2328871848.SGD","BK0010","SGXZ81163826.USD","LU1820825898.SGD","600000","LU0011963245.USD","BK0060","BK0278","LU0231483743.USD","LU1997245094.SGD","BK0239","00656","LU0029874905.USD","BK0253","LU1781817850.SGD","LU1808992512.USD","LU2580892862.HKD","LU0047713382.USD","LU0140636845.USD","LU1255011170.USD","LU2097828714.EUR","LU2097828474.EUR","BK0196","SGXZ49509284.SGD","BK0183","LU0708995153.HKD","LU2495084118.USD","LU1048596156.SGD","601818","LU0543330566.HKD","LU1934453819.USD","LU2148510915.USD","601169","LU0229945570.USD","LU2097828631.EUR","BK0086","600196","BK0028","600398","SG9999001903.USD","SG9999006597.SGD","LU1997245177.USD","HK0000181112.HKD","600015","BK0201","LU1969619763.USD","LU2213484517.USD","SG9999000459.SGD"],"gpt_icon":0},{"id":"2608859128","title":"SANJOSE Wins Contract to Build Six Iconic Buildings in Lisbon's Entrecampos","url":"https://stock-news.laohu8.com/highlight/detail?id=2608859128","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608859128?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:36","pubTimestamp":1770021400,"startTime":"0","endTime":"0","summary":"Grupo Empresarial SANJOSE SA, through its subsidiary SANJOSE Portugal, has been awarded the contract by Fidelidade Property Europe to construct six new iconic buildings in Lisbon’s Entrecampos district. The project spans 154,000 square meters and will feature office space on the upper floors, commercial areas on the lower levels, and underground parking. Designed by KPF in collaboration with Saraiva + Associados, the development emphasizes sustainability and innovation, aiming for LEED Gold, WELL Gold, and WiredScore certifications. The architectural design incorporates public spaces, terraces, and lively plazas, setting a new benchmark for urban development in Portugal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grupo Empresarial ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5StcRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"1170402510","title":"Guo Guangchang: Fosun Believes Exceptional Products and Sincere Experiences Can Win Hearts","url":"https://stock-news.laohu8.com/highlight/detail?id=1170402510","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170402510?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:50","pubTimestamp":1769997048,"startTime":"0","endTime":"0","summary":"On the evening of February 1st, Guo Guangchang, Chairman of Fosun Group, posted on Weibo that after finishing a day's work, he took a night tour of the 2026 Yuyuan Lantern Festival and shared the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2608788413","title":"Is Fosun International (SEHK:656) Offering Value After Prolonged Share Price Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2608788413","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608788413?lang=en_us&edition=fundamental","pubTime":"2026-02-02 02:25","pubTimestamp":1769970312,"startTime":"0","endTime":"0","summary":"If you are wondering whether Fosun International's share price reflects its underlying value, you are not alone. This article is designed to help you frame that question clearly.\nThe stock last closed at HK$4.16, with returns of 0.2% over 7 days, a 5.0% decline over 30 days, a 5.2% decline year to date, and a 1.7% decline over 1 year. The 3 year and 5 year returns show declines of 43.4% and 61.6% respectively.\nThese price moves have put valuation back on many investors' radar, especially as...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/is-fosun-international-sehk656-offering-value-after-prolonge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/is-fosun-international-sehk656-offering-value-after-prolonge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1230","00656","DCF"],"gpt_icon":0},{"id":"2607370845","title":"BUZZ-Indian shares slip after two sessions of gains as IT, auto weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2607370845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607370845?lang=en_us&edition=fundamental","pubTime":"2026-01-29 14:48","pubTimestamp":1769669339,"startTime":"0","endTime":"0","summary":"BUZZ-Indian shares slip after two sessions of gains as IT, auto weigh** India's stock benchmarks Nifty 50 .NSEI and Sensex .BSESN lose 0.3% each, dragged by lower IT stocks after the U.S. Fed's rate pause and a fall in auto stocks on Maruti Suzuki's MRTI.NS quarterly profit miss** Both Nifty and Sensex gained 1% in last two sessions, with sentiment supported by the India-EU trade deal** Half of 16 major sectors decline; IT companies .NIFTYIT, which earn a major share of revenue from the U.S., fall 1.5%; Fed kept policy interest rate steady overnight and investors are not expecting any rate cut till June ** High U.S. rates make emerging markets such as India less attractive for overseas investors** Auto index .NIFTYAUTO falls 1.7%, with Maruti Suzuki MRTI.NS losing 3% after posting lower-than-expected quarterly profit, hurt by a one-time charge due to new labour code and higher raw material costs** Broader small- .NIFSMCP100 and mid-caps .NIFMDCP100 fall 0.3% and 0.6%, respectively** La","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU0OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2607771206","title":"INDIA STOCKS-IT, auto shares drag Indian benchmarks lower ahead of federal budget","url":"https://stock-news.laohu8.com/highlight/detail?id=2607771206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607771206?lang=en_us&edition=fundamental","pubTime":"2026-01-29 12:39","pubTimestamp":1769661577,"startTime":"0","endTime":"0","summary":"INDIA STOCKS-IT, auto shares drag Indian benchmarks lower ahead of federal budgetUpdates for morning tradeBy Bharath Rajeswaran","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU0EK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2607779422","title":"BUZZ-India's Gland Pharma hits more than 2-month high on strong Q3 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779422","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779422?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:55","pubTimestamp":1769658903,"startTime":"0","endTime":"0","summary":"BUZZ-India's Gland Pharma hits more than 2-month high on strong Q3 results** India's Gland Pharma GLAD.NS climbs 8.8% to 1,837.30 rupees, its highest since Nov 14 ** Drugmaker reports 28% jump in Q3 profit, supported by strong sales in the key European and U.S. markets** Q3 Rev from ops rises 22.5% to 16.95 billion Indian rupees ** Stock top gainer on pharma index .NIPHARM, which is down 0.3%** Nomura upgrades stock to \"Buy\" from \"Neutral\"; says riskreward now appears favorable given recent earnings revisions and the stock’s correction** Gland is taking the right steps to improve visibility for future growth and expects base business to grow in doubledigits in FY27 and earnings to normalize in FY28E** Avg rating on GLAD at \"Hold\"; median PT is 2,054.50 rupees - data compiled by LSEG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU0ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2607744630","title":"Deutsche Bank Ag and Its Asset Manager Dws Group Are Considering Taking a Significant Minority Stake in a Fosun International Controlled Life Insurance Consolidator- Bloomberg News (Fixes to Clarify Co's Not Exploring Stake in Fosun)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607744630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607744630?lang=en_us&edition=fundamental","pubTime":"2026-01-29 02:56","pubTimestamp":1769626617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL8N3YT2I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2607741481","title":"BRIEF-Deutsche Bank AG And Its Asset Manager Dws Group Are Considering Taking A Significant Minority Stake In A Fosun International - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2607741481","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607741481?lang=en_us&edition=fundamental","pubTime":"2026-01-29 02:28","pubTimestamp":1769624898,"startTime":"0","endTime":"0","summary":"BRIEF-Deutsche Bank AG And Its Asset Manager Dws Group Are Considering Taking A Significant Minority Stake In A Fosun International - Bloomberg NewsJan 28 (Reuters) - DEUTSCHE BANK AG AND ITS ASSET MA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT161:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2607741485","title":"Deutsche Bank Ag and Its Asset Manager Dws Group Are Considering Taking a Significant Minority Stake in a Fosun International - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2607741485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607741485?lang=en_us&edition=fundamental","pubTime":"2026-01-29 02:27","pubTimestamp":1769624850,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT161:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2606971316","title":"Gland Pharma Q3 Consol Net Profit 2.61 Billion Rupees vs IBES Est. 2.44 Billion Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2606971316","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606971316?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:51","pubTimestamp":1769601088,"startTime":"0","endTime":"0","summary":"Jan 28 (Reuters) - Gland Pharma Ltd ::*Q3 CONSOL NET PROFIT 2.61 BILLION RUPEES; IBES EST. 2.44 BILLION RUPEES*Q3 CONSOL REVENUE FROM OPERATIONS 16.95 BILLION RUPEES; IBES EST. 15.87 BILLION RUPEES*Fu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nRSD8Bmd18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2606760337","title":"BUZZ-Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2606760337","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606760337?lang=en_us&edition=fundamental","pubTime":"2026-01-28 15:00","pubTimestamp":1769583615,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval** Shanghai Henlius Biotech 2696.HK stock surges 7.7% to HK$58.8, set for biggest one-day gain since Oct 8** Stock hits highest level since Jan 23, snapping 7-session losing streak** China's drug regulator approves clinical trial for antibody-drug conjugate HLX43 combined with monoclonal antibody HLX07 for advanced solid tumours, co says** Company says it intends to commence the relevant clinical trials in mainland China when conditions are met** YTD, stock up 2.1%, Hang Seng Biotech Index .HSBIO up 11.8%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL1N3YT09D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","00656","BK1230","BK1161","HK0000320223.HKD","HK0000306701.USD","02696"],"gpt_icon":0},{"id":"2606202176","title":"Henlius Biotech Wins Approval for Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2606202176","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606202176?lang=en_us&edition=fundamental","pubTime":"2026-01-27 17:27","pubTimestamp":1769506059,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration has approved the application for a clinical trial of HLX43 for injection, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07  and HANSIZHUANG  for the treatment of advanced solid tumours. According to the company, as of the date of the announcement, no similar combination therapy has been approved for marketing globally. The company cautioned that there is no guarantee of successful development or commercialisation of HLX43 and HLX07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL9fBljQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1161","BK1230","HK0000320264.USD","00656","02696","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2606653259","title":"Fosun International (HKG:656) shareholders have endured a 62% loss from investing in the stock five years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2606653259","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606653259?lang=en_us&edition=fundamental","pubTime":"2026-01-25 10:36","pubTimestamp":1769308610,"startTime":"0","endTime":"0","summary":"Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/fosun-international-hkg656-shareholders-have-endured-a-62-lo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/fosun-international-hkg656-shareholders-have-endured-a-62-lo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2605269864","title":"BUZZ-Shanghai Fosun Pharmaceutical climbs on vaccine unit's Hong Kong listing plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2605269864","media":"Reuters","labels":["shareholding","corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605269864?lang=en_us&edition=fundamental","pubTime":"2026-01-23 13:54","pubTimestamp":1769147668,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Fosun Pharmaceutical climbs on vaccine unit's Hong Kong listing plan** Shanghai Fosun Pharmaceutical's Hong Kong shares 2196.HK climb 3.1% to HK$20.86, set for biggest one-day pct gain since Jan 13** Shanghai-listed stock 600196.SS adds 1.7% to 27.72 yuan, biggest one-day pct rise since Jan 5** Healthcare group's board of directors approves proposed spin-off and listing of vaccine unit Fosun Adgenvax  Biopharmaceutical in Hong Kong** Spin-off and listing subject to shareholder, China Securities Regulatory Commission, the Stock Exchange and other authorities approvals - co** YTD, Hong Kong stock up 5.2%, Shanghai-listed shares up 3.9%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nL1N3YO04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0096","02196","BK0028","BK0188","BK0187","BK1515","BK0183","BK1593","BK0175","BK1191","BK1230","BK0060","00656","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2605495004","title":"Shanghai Fosun Pharmaceutical Subsidiary Receives Drug Registration Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495004","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495004?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:25","pubTimestamp":1769084712,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co., Ltd. announced that a subsidiary has received approval for drug registration. According to the company, the approval covers a pharmaceutical product and is expected to further enrich the group's product line. The company noted that the sales performance following market launch may be subject to various factors, including demand, market competition, and sales channels, and investors are advised to consider associated risks. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL8pzrg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0060","00656","BK0188","BK1230","600196","BK0196","BK0239","BK0187","BK0028","BK0175","BK0096","BK0183"],"gpt_icon":0},{"id":"2605498326","title":"Fosun Pharma Subsidiary Fosun Adgenvax Plans Spin-Off Listing on Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2605498326","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605498326?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:20","pubTimestamp":1769080815,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Proposes Spin-Off Listing of Subsidiary Fosun Adgenvax. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL8DSvmj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","00656","BK1230","BK0183","BK0028","BK0096","BK0012","BK0175","600196","BK0060","BK0187","BK0196","BK0239"],"gpt_icon":0},{"id":"2605830177","title":"Sisram Medical Signs MOU for Localisation Cooperation with Sinmait Medical in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2605830177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605830177?lang=en_us&edition=fundamental","pubTime":"2026-01-21 17:14","pubTimestamp":1768986887,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd. has announced the signing of a memorandum of understanding  with Sinmait Medical Technology  Co., Ltd., an indirect wholly owned subsidiary of Shanghai Fosun Pharmaceutical  Co., Ltd. The MOU sets the framework for a possible cooperation aimed at promoting localisation in the People’s Republic of China. The cooperation is still subject to the signing of definitive agreements and may or may not proceed. If finalised, the partnership may constitute a notifiable and/or connected transaction under Hong Kong listing rules. Sisram Medical will provide further updates as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLNRVL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01696","BK0187","BK0060","BK0096","BK1100","00656","BK1585","BK0188","BK0012","BK1230","BK1593","BK0175","BK0239","BK0183","BK0028","600196","BK0196"],"gpt_icon":0},{"id":"2605074172","title":"Fosun International Receives Higher FTSE Russell ESG Score and Maintains Inclusion in FTSE4Good Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2605074172","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605074172?lang=en_us&edition=fundamental","pubTime":"2026-01-21 17:11","pubTimestamp":1768986709,"startTime":"0","endTime":"0","summary":"Fosun International Limited announced that its FTSE Russell ESG score has risen to 4.2, and the company has been included in the FTSE4Good Index Series for the fifth consecutive time. The company reported full scores of 5.0 in Environmental Supply Chain, Anti-Corruption, Risk Management, Social Supply Chain, and Corporate Governance. Fosun International also noted scores of 4.0 or above in Labour Standards, Health & Safety, Customer Responsibility, and Human Rights & Community. Additionally, Fosun International maintained an MSCI ESG rating of AA and an HSI ESG rating of AA-, and was included in S&P Global's Sustainability Yearbook 2025 and its China Edition top 1%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Lim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL1T5RD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0969580561.USD","LU0472753341.HKD","LU0345774631.USD","LU1989763005.USD","LU0069063385.USD","BK4588","LU0158827948.USD","LU2089284900.SGD","BK1230","LU0171293334.USD","LU0171276677.USD","LU0971096721.USD","IE00BKPKM429.USD","LU1989772840.SGD","IE00BQXX3C00.GBP","LU1496350502.SGD","LU1363072403.SGD","LU1496350171.SGD","LU2265009873.SGD","LU0526926950.USD","LSEG.UK","LU1989773731.SGD","SG9999014898.SGD","LU2089283258.USD","LU1019634622.SGD","IE00BKPKM643.USD","LU2210150020.SGD","LU0545562505.USD","LU2506952170.USD","BK4585","IE00BQXX3F31.USD","SG9999014914.USD","LU1228905037.USD","00656","LU2764262908.HKD","LU0345777147.USD","LU0788108743.HKD","LU1989764748.USD","SPGI","SGXZ31699556.SGD","LU0289739343.SGD","LU0175139822.USD","LU0823417653.USD","IE0004086264.USD","LU2264538146.SGD","BK4534","LU0985320562.USD","LU0171280430.USD","LU1989772923.USD","IE0004091025.USD"],"gpt_icon":0},{"id":"2604193766","title":"Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2604193766","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604193766?lang=en_us&edition=fundamental","pubTime":"2026-01-20 16:58","pubTimestamp":1768899512,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the investigational new drug  application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer, has been approved by the National Medical Products Administration. As of the date of the announcement, no SIRPα-Fc fusion protein targeting CD47 has been approved for marketing globally. The company noted that successful development and commercialization of HLX701 cannot be guaranteed and advised shareholders and potential investors to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5w1DjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000306701.USD","BK1230","00656","BK1161","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","02696"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosun.com","stockEarnings":[{"period":"1week","weight":-0.0096},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.1435},{"period":"6month","weight":-0.2328},{"period":"1year","weight":-0.0101},{"period":"ytd","weight":-0.0594}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Fosun International Ltd is a company principally engaged in the operation and investments in global consumer business. The Company operates its business through five segments. The Happiness segment engages in the operation and investments in tourism and leisure, fashion consumer and lifestyle industries. The Health segment engages in the research and development, manufacture, sale and trading of pharmaceutical and health products and providing medical services and health management. The Insurance segment mainly engages in the operation of and investment in the insurance businesses. The Asset Management segment comprises principally the operation and investment of asset management, market investments, and investments in other companies of the Group. The Intelligent Manufacturing segment comprises principally the operation of and investment in the intelligent manufacturing and iron, steel, new functional materials and ore production.","yearOnYearQuotes":[{"month":1,"riseRate":0.631579,"avgChangeRate":0.0049},{"month":2,"riseRate":0.473684,"avgChangeRate":0.013259},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000408},{"month":4,"riseRate":0.555556,"avgChangeRate":0.034582},{"month":5,"riseRate":0.555556,"avgChangeRate":0.040571},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.012529},{"month":7,"riseRate":0.388889,"avgChangeRate":0.000713},{"month":8,"riseRate":0.105263,"avgChangeRate":-0.050815},{"month":9,"riseRate":0.578947,"avgChangeRate":-0.012339},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.019588},{"month":11,"riseRate":0.473684,"avgChangeRate":0.019122},{"month":12,"riseRate":0.526316,"avgChangeRate":0.020584}],"exchange":"SEHK","name":"FOSUN INTL","nameEN":"FOSUN INTL"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FOSUN INTL,00656,FOSUN INTL股票,FOSUN INTL股票老虎,FOSUN INTL股票老虎国际,FOSUN INTL行情,FOSUN INTL股票行情,FOSUN INTL股价,FOSUN INTL股市,FOSUN INTL股票价格,FOSUN INTL股票交易,FOSUN INTL股票购买,FOSUN INTL股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}